Tejnaksh Healthcare Ltd (539428)
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Tejnaksh Healthcare's revenue was ₹2.7 Cr (+0.5% year on year, +4.1% on the previous quarter), and net profit ₹0.3 Cr (+24.1% year on year); the operating margin was 26.0%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹2.7 | +0.5% | +4.1% |
| Operating profit | ₹0.7 | +14.9% | -2.9% |
| Net profit | ₹0.3 | +24.1% | -25.5% |
| EPS (₹) | 0.13 | +8.3% | -27.8% |
| Operating margin | 26.0% | — | — |
📢 Recent Corporate Announcements
Tejnaksh Healthcare has submitted its Annual Report for FY 2025-26 and announced its 19th Annual General Meeting scheduled for September 29, 2026, via Video Conferencing. Key agenda items include the adoption of FY26 audited financial statements and the re-appointment of Independent Director Mr. Suhas Vasantrao Thorat for a 5-year term until August 2031. Additionally, the company seeks shareholder approval for material related party transactions capped at up to Rs 100 Lakhs per category per year with entities including promoter Dr. Ashish Rawandale and subsidiary Tej Vedaant Healthcare.
- 19th Annual General Meeting to be held on Tuesday, 29th September, 2026 at 3:00 PM via VC/OAVM.
- Proposed re-appointment of Independent Director Mr. Suhas Vasantrao Thorat for a second 5-year term from August 13, 2026 to August 12, 2031.
- Approval sought for related party transactions up to Rs 100 Lakhs per category annually with promoter Dr. Ashish Rawandale and subsidiary Tej Vedaant Healthcare.
- VC attendance capped at 1,000 members on a first-come, first-served basis (excluding promoters and large shareholders).
Tejnaksh Healthcare reported a standalone total income of Rs 1.93 Cr for Q1 FY27, a marginal 3.7% increase compared to Rs 1.86 Cr in the same quarter last year. Net profit declined by 13.7% YoY to Rs 29.11 Lakhs, down from Rs 33.73 Lakhs, primarily due to an increase in other expenses. The current quarter's revenue represents only 17.5% of the TTM revenue of Rs 11 Cr, indicating a slow start to the financial year. The company remains debt-free but is operating at a very small scale with stagnant growth.
- Total income for Q1 FY27 stood at Rs 1.93 Cr, compared to Rs 1.86 Cr in Q1 FY26.
- Net profit after tax fell to Rs 29.11 Lakhs from Rs 33.73 Lakhs in the year-ago period.
- Other expenses rose to Rs 87.66 Lakhs, representing approximately 45% of total income.
- Earnings Per Share (EPS) for the quarter was Rs 0.14, down from Rs 0.17 in Q1 FY26.
- A reversal of gratuity liability was recognized as other income following the implementation of New Labour Codes.
Tejnaksh Healthcare reported a standalone net profit of ₹0.29 Cr for the quarter ended June 30, 2026, representing a 42.2% decline from the ₹0.50 Cr reported in the previous quarter (March 2026). Revenue from operations remained relatively flat sequentially at ₹1.93 Cr compared to ₹1.92 Cr in Q4 FY26, though it grew 3.7% year-on-year. The company's profitability was impacted by a rise in 'Other expenses', which increased to ₹87.66 lakhs from ₹76.58 lakhs in the preceding quarter. Additionally, the board approved the reappointment of Suhas Vasantrao Thorat as an Independent Director for a second term.
- Standalone revenue from operations for Q1 FY27 stood at ₹1.93 Cr, a marginal 3.7% increase over ₹1.86 Cr in Q1 FY26.
- Net profit for the quarter was ₹29.11 lakhs, down from ₹50.41 lakhs in the previous quarter (March 2026).
- Total expenses rose to ₹1.48 Cr in Q1 FY27, compared to ₹1.30 Cr in the previous quarter.
- Earnings Per Share (EPS) for the quarter decreased to ₹0.14 from ₹0.39 in the preceding quarter.
- Reappointment of Mr. Suhas Vasantrao Thorat as a Non-Executive Independent Director for a second term, subject to shareholder approval.
Tejnaksh Healthcare has scheduled a board meeting for August 13, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026. The board will also deliberate on the reappointment of Mr. Suhas Vasantrao Thorat as an Independent Director for a second term. This meeting is critical as the company seeks to stabilize performance following a revenue decline from Rs 12.9 Cr in FY25 to Rs 10.79 Cr in FY26. The company currently maintains a debt-free balance sheet with a market capitalization of Rs 26 Cr.
- Board meeting scheduled for August 13, 2026, to approve Q1 FY27 results.
- Proposal for reappointment of Independent Director Suhas Vasantrao Thorat (DIN: 09241231) for a second term.
- Trading window has been closed since June 25, 2026, in compliance with insider trading regulations.
- Company reported TTM revenue of Rs 11 Cr and TTM PAT of Rs 1 Cr as of the latest available data.
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
